LLY
Eli Lilly andANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The Q1 filing confirms exceptional revenue and earnings scale, and Lilly still has a rare combination of commercial momentum and obesity/cardiometabolic pipeline optionality. If retatrutide and other follow-on programs keep delivering, the premium valuation can remain defensible.
Posture
Constructive
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Clinical-trial timing, regulatory approval, and readout uncertainty remain material because Lilly's pipeline value depends on continued execution.
Momentum
83
Value
59
Sentiment
55
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $1,160.00 · Bull $1,325.00 · Bear $930.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $1,247.39
Why
Momentum83 · Δ7d +9.1
Value59 · Δ7d +0.1
Sentiment55 · Δ7d -8.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
83
34% active weight
Current posture
7d trendImproving
Δ7d
+9.1
Δ21d
+49.2
Value
59
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
55
33% active weight
Current posture
7d trendSoftening
Δ7d
-8.4
Δ21d
-2.7
Why this grade
Composite grade A. Momentum 83.1 / Value 58.8 / Sentiment 55.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.02T
Beta
0.39
Shares Out
945.38M
P/E (TTM)
50.9
P/S (TTM)
16.57
P/FCF (TTM)
800.77
Rev YoY
+53.9%
EPS YoY
+479.3%
Gross Margin
+83.0%
Op Margin
+38.8%
Net Debt
$30.22B
Current Ratio
1.55
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology